These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 36831387)
1. Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition. Islam S; Rahaman MH; Yu M; Noll B; Martin JH; Wang S; Head R Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831387 [TBL] [Abstract][Full Text] [Related]
2. Combined Islam S; Teo T; Kumarasiri M; Slater M; Martin JH; Wang S; Head R Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297298 [TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. Grundy M; Seedhouse C; Russell NH; Pallis M BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421 [TBL] [Abstract][Full Text] [Related]
4. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249 [TBL] [Abstract][Full Text] [Related]
5. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131 [TBL] [Abstract][Full Text] [Related]
6. Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology. Pereira M; Vale N Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769210 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia. Qi J; Gao X; Zhong X; Zhang N; Wang R; Zhang H; Pan T; Liu X; Yao Y; Wu Q; Niu M; Xu K Biomed Pharmacother; 2019 Sep; 117():109113. PubMed ID: 31207577 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases. Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633 [TBL] [Abstract][Full Text] [Related]
9. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Huang XF; Luo SK; Xu J; Li J; Xu DR; Wang LH; Yan M; Wang XR; Wan XB; Zheng FM; Zeng YX; Liu Q Blood; 2008 Mar; 111(5):2854-65. PubMed ID: 18160664 [TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. McLaughlin J; Markovtsov V; Li H; Wong S; Gelman M; Zhu Y; Franci C; Lang D; Pali E; Lasaga J; Low C; Zhao F; Chang B; Gururaja TL; Xu W; Baluom M; Sweeny D; Carroll D; Sran A; Thota S; Parmer M; Romane A; Clemens G; Grossbard E; Qu K; Jenkins Y; Kinoshita T; Taylor V; Holland SJ; Argade A; Singh R; Pine P; Payan DG; Hitoshi Y J Cancer Res Clin Oncol; 2010 Jan; 136(1):99-113. PubMed ID: 19609559 [TBL] [Abstract][Full Text] [Related]
11. Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression. Heo SK; Noh EK; Jeong YK; Ju LJ; Sung JY; Yu HM; Cheon J; Koh S; Min YJ; Choi Y; Jo JC Tumour Biol; 2019 May; 41(5):1010428319848612. PubMed ID: 31074363 [TBL] [Abstract][Full Text] [Related]
12. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775 [TBL] [Abstract][Full Text] [Related]
13. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells. Lu C; Hassan HT Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192 [TBL] [Abstract][Full Text] [Related]
14. Purging human ovarian cortex of contaminating leukaemic cells by targeting the mitotic catastrophe signalling pathway. Eijkenboom L; Mulder C; van der Reijden B; van Mello N; van Leersum J; Koorenhof-Scheele T; Braat D; Beerendonk C; Peek R J Assist Reprod Genet; 2021 Jun; 38(6):1571-1588. PubMed ID: 33725274 [TBL] [Abstract][Full Text] [Related]
15. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Hassan HT Leuk Res; 2004 Jul; 28(7):667-71. PubMed ID: 15158086 [TBL] [Abstract][Full Text] [Related]
16. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107 [TBL] [Abstract][Full Text] [Related]
17. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles. Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940 [TBL] [Abstract][Full Text] [Related]
18. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807 [TBL] [Abstract][Full Text] [Related]
19. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926 [TBL] [Abstract][Full Text] [Related]
20. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Zhou Y; Shan S; Li ZB; Xin LJ; Pan DS; Yang QJ; Liu YP; Yue XP; Liu XR; Gao JZ; Zhang JW; Ning ZQ; Lu XP Cancer Sci; 2017 Mar; 108(3):469-477. PubMed ID: 28004478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]